PMV Pharmaceuticals(PMVP)2024-11-07 13:00Clinical Trials - Enrollment in the Phase 2 portion of the PYNNACLE clinical trial is on track, with over 75% of sites activated across the U.S., Europe, and Asia-Pacific, and interim analysis expected by mid-2025[1][2] - The Phase 1b study in collaboration with MD Anderson and Memorial Sloan Kettering is set to begin enrollment in Q1 2025, evaluating rezatapopt monotherapy and in combination with azacitidine in approximately 25 patients[1][3] - The ongoing Phase 1/2 PYNNACLE trial has achieved an overall response rate of 38% at the recommended Phase 2 dose of 2000 mg daily[1][9] Financial Performance - PMV Pharmaceuticals has 238.1 million a year earlier, providing a cash runway expected to last until the end of 2026[1][6] - The net loss for Q3 2024 was 16.6 million in Q3 2023, primarily due to increased R&D spending[1][6] - R&D expenses for Q3 2024 were 13.6 million in Q3 2023, reflecting higher contract research organization costs[1][6] - General and administrative expenses decreased to 6.0 million in Q3 2023, attributed to reduced facility and operational spending[1][6] Drug Development - Rezatapopt showed a 42% increase in exposure levels when taken with food, supporting the recommendation for the 2000 mg once-daily dose to be administered with food[1][4] - The maximum tolerated dose for the combination of rezatapopt and KEYTRUDA was established at 500 mg once-daily, but enrollment in this arm was discontinued due to limited clinical benefit[1][5] - PMV Pharmaceuticals anticipates filing a New Drug Application for rezatapopt by the end of 2026[1][2]